US regulatory status: approved.
pharma · RSV Infection · NASH - Nonalcoholic Steatohepatitis · ENTA
ENANTA PHARMACEUTICALS
ENANTA PHARMACEUTICALS INC
ENANTA PHARMACEUTICALS drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
4 Kingsbury Ave, Watertown, Massachusetts 02472, US HQ
1995 Founded
145 Employees
Public company Type
ENTA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4 Kingsbury Ave, Watertown, Massachusetts 02472, US
- Founded
- 1995
- Employees
- 145
- Programs
- 34
- Drugs
- 15
- Patents
- 218
ENANTA PHARMACEUTICALS pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ENANTA PHARMACEUTICALS drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in ENANTA PHARMACEUTICALS's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in ENANTA PHARMACEUTICALS's portfolio.
-
Development asset linked to ENANTA PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to ENANTA PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to ENANTA PHARMACEUTICALS in public FDA and regional records.
-
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in ENANTA PHARMACEUTICALS's portfolio. Molecular target: Fusion glycoprotein F0.
- Target
- Fusion glycoprotein F0
- Mechanism
- Fusion glycoprotein F0 vaccine antigen
-
Development asset linked to ENANTA PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to ENANTA PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to ENANTA PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to ENANTA PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to ENANTA PHARMACEUTICALS in public FDA and regional records.